Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors

NCT05269316 is registered in ClinicalTrials.gov with Impact Therapeutics, Inc. as lead sponsor.

NCT NCT05269316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05269316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors
Lead sponsor
Impact Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 11, 2022
Completion date
December 31, 2026
Enrollment
61 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, solid tumor